Skip to main content

Table 1 Potencies (μM, mean ± SEM) of lesinurad, benzbromarone, and probenecid against the resorptive uric acid transporters URAT1, OAT4, and GLUT9

From: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

  Reabsorptive uric acid transporter
Compound URAT1 OAT4 GLUT9
Lesinurad 3.53 ± 0.52 2.03 ± 0.66 >100
Benzbromarone 0.29 ± 0.06 3.19 ± 1.04 ~100
Probenecid 13.23 ± 0.44 15.54 ± 3.39 ND
  1. Results are from three experimentsfree concentration